MAIL ONLINE: Immunotherapy drug which could stall lung cancer for up to five years and even CURE it will now be funded by the NHS

Press/Media: Expert comment

Description

Corinne Faivre-Finn, an oncology professor at the University of Manchester, said: 'The availability of durvalumab is a watershed moment for lung cancer in England as it will change how we treat patients with stage 3 disease.

'Stage three non-small cell lung cancer is potentially curable but unfortunately with current treatments most patients will progress to advanced disease.

'Now, for the first time in 20 years, we have access to a new treatment option that has been shown to improve survival outcomes.'

Period28 Mar 2019

Media contributions

1

Media contributions

  • TitleImmunotherapy drug which could stall lung cancer for up to five years and even CURE it will now be funded by the NHS
    Media name/outletMail Online
    Media typeWeb
    Country/TerritoryUnited Kingdom
    Date28/03/19
    DescriptionCorinne Faivre-Finn, an oncology professor at the University of Manchester, said: 'The availability of durvalumab is a watershed moment for lung cancer in England as it will change how we treat patients with stage 3 disease.

    'Stage three non-small cell lung cancer is potentially curable but unfortunately with current treatments most patients will progress to advanced disease.

    'Now, for the first time in 20 years, we have access to a new treatment option that has been shown to improve survival outcomes.'
    URLhttps://www.dailymail.co.uk/health/article-6856879/Immunotherapy-drug-stall-lung-cancer-five-years-funded-NHS.html?ns_mchannel=rss&ito=1490&ns_campaign=1490
    PersonsCorinne Faivre-Finn
View all 1
View less

Research Beacons, Institutes and Platforms

  • Cancer

Keywords

  • cancer